pentadecapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-12. Numbers and descriptions here follow the published literature rather than marketing material.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
| Property | Value | Notes |
|---|---|---|
| Appearance | white to off-white powder | lyophilized form |
| Typical purity | 95 percent or higher by RP-HPLC | value depends on method |
| Storage temperature | minus 20 degrees Celsius or below | desiccated, protected from light |
| Reconstitution solvent | bacteriostatic water | sterile saline also used |
| Primary assay | RP-HPLC with UV detection | often paired with mass spectrometry |
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
On 22 December 1988, the Brazzaville Protocol was enshrined in the Tripartite Accord, which required the SADF to withdraw from Angola and reduce its troop levels in South West Africa to a token force of 1,500 within twelve weeks. Simultaneously, all Cuban brigades would be withdrawn from the border to an area north of the 15th parallel. At least 3,000 Cuban military personnel would depart Angola by April 1989, with another 25,000 leaving within the next six months. The remaining troops would depart at a date not later than 1 July 1991. An additional condition was that South Africa would cease all support for UNITA, and Angola likewise for PLAN and MK. On 20 December 1988, United Nations Security Council Resolution 626 was passed, creating the United Nations Angola Verification Mission (UNAVEM) to verify the redeployment northwards and subsequent withdrawal of the Cuban forces from Angola. UNAVEM included observers from Western as well as non-aligned and communist nations. In February 1989 the United Nations Transition Assistance Group (UNTAG) was formed to monitor the South West African peace process.
But severe indoor air quality conditions also can emerge in affluent, highly-developed locales; for example, children fell sick from indoor mold in an apartment complex in Riviera Beach, Florida. Typically, poor indoor air quality is often related to cooking and heating methods by burning biomass fuel, in the form of wood, charcoal, dung, and crop residue, in indoor environments that lack proper ventilation. Millions of people, primarily women and children, face serious health risks. In total, about three billion people in developing countries are affected by this problem. The World Health Organization (WHO) estimates that cooking-related indoor air pollution causes 3.8 million annual deaths. The Global Burden of Disease study estimated the number of deaths in 2017 at 1.6 million.
== Ionization mechanisms == The photoionization mechanism is simplified under vacuum conditions: photon absorption by the analyte molecule, leading to electron ejection, forming a molecular radical cation, M•+. This process is similar to electron ionization common to GC/MS, except that the ionization process is soft, i.e., less fragmentation. In the atmospheric region of an LC/MS system, the ionization mechanism becomes more complex. The unpredictable fate of ions is generally detrimental to LC/MS analysis, but like most processes, once they are better understood, these properties can be exploited to enhance performance. For example, the role of dopant in APPI, first developed and patented for the atmospheric ion source of ion mobility spectrometry (IMS), was adapted to APPI for LC/MS. The basic APPI mechanisms can be summarized by the following scheme: Direct positive ion APPI
=== Dispute with Vivendi === On September 20, 2004, GameSpot reported that Sierra's parent company, Vivendi Universal Games, was in a legal battle with Valve over the distribution of Half-Life 2 to cyber cafés. Cyber cafés were important for the gaming market in Asia, where PC and broadband penetration per capita were much lower in most territories. According to Vivendi, the distribution contract they signed with Valve included cyber cafés. This would mean that only Vivendi could distribute Half-Life 2 to cyber cafés — not Valve through the Steam system. On November 29, 2004, Judge Thomas S. Zilly, of U.S. Federal District Court in Seattle, Washington, ruled that Vivendi and its affiliates were not authorized to distribute (directly or indirectly) Valve games through cyber cafés for pay-to-play activities according to the parties' current publishing agreement. Zilly also ruled in favor of the Valve motion regarding the contractual limitation of liability, allowing Valve to recover copyright damages for any infringement as allowed by law without regard to the publishing agreement's limitation of liability clause. On April 29, 2005, Valve and Vivendi announced a settlement. Vivendi would cease distributing all retail packaged versions of Valve games by August 31, 2005. Vivendi was also to notify distributors and cyber cafés that had been licensed by Vivendi that only Valve had the authority to distribute cyber café licenses; their licenses were revoked and switched to Valve's.
Sources: en.wikipedia.org
In spite of 2018 election promises that "not a single person will lose their job" under his PC government, Ontario Health Minister Christine Elliot office announced in June 2019 that 416 workers would be laid off, as 20 health agencies, including 14 local health integration networks (LHINs), Cancer Care Ontario, eHealth Ontario were merged into one new super-agency called Ontario Health. With the merger "another 409 vacant positions will be eliminated." These changes are estimated to save "$350 million a year by 2021–22". A CBC News report said that the average wait times in Ontario hospitals set a new June record of an average of 16.3 hours waiting in emergency rooms in 2019, compared to 14.4 hours in June 2018, based on Health Quality Ontario data. More restructuring was announced by the Health ministry in September and no more job losses are anticipated. On November 18, 2024, Ford's government tabled a bill to ban supervised injection sites from operating within 200 meters of a school or child-care centre. The bill would also require municipalities to get approval from the provincial health minister and federal government before launching new facilities. In a news conference for the bill, Health Minister Sylvia Jones stated, "I want to be very clear, there will be no further safe injection sites in the province of Ontario under our government."
The meanings of the various colors are standardized by the Clinical and Laboratory Standards Institute and are the same across manufacturers. The term order of draw refers to the sequence in which tubes should be filled. The needle which pierces the tubes can carry additives from one tube into the next, so the sequence is standardized so that any cross-contamination of additives will not affect laboratory results.
RN=C=NR ↔ RN+≡C-N−R ↔ RN−-C≡N+R The N=C=N core is relatively linear and the C-N=C angles approach 120°. In the case of C(NCHPh2)2, the central N=C=N angle is 170° and the C-N=C angles are within 1° of 126°. The C=N distances are short, nearly 120 pm, as is characteristic of double bonds. Carbodiimides are chiral, possessing C2-symmetry and therefore axial chirality. However, due to the low energy barrier to the molecule rotating and thereby converting quickly between its isomers, the actual isolation of one optical isomer of a carbodiimide is extremely difficult. It has been demonstrated at least once, in the case of conformationally restricted cyclic carbodiimides; though there are other reports of one-handed axially chiral carbodiimides, their validity has since been called into question on experimental and computational grounds. The parent compound, methanediimine, (HN=C=NH), is a tautomer of cyanamide.
Sources: en.wikipedia.org
Bacteriostatic water or sterile saline is commonly used to dissolve the powder. The choice of solvent affects stability and preservation. Aqueous solutions are kept refrigerated and are not intended for long-term storage.
Most suppliers state a purity of ninety-five percent or higher by reversed-phase chromatography. Values below that threshold indicate a larger proportion of related peptides. The reported figure depends on the detection wavelength, usually 214 nanometers for peptides.
Sealed vials kept cold and dry retain potency for years in many cases. Exposure to warmth or moisture accelerates degradation. A stated expiration date is a supplier estimate rather than a measured endpoint.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.